查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
药物发现和下一代治疗中的合成生物学 (SynBio)
市场调查报告书
商品编码
1308048

药物发现和下一代治疗中的合成生物学 (SynBio)

Synthetic Biology (SynBio) in Drug Discovery and Next-generation Therapeutics
出版日期: | 出版商: Frost & Sullivan | 英文 71 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

合成生物学（SynBio）颠覆性技术的进步，以培育繁荣的利益相关者生态系统并加速生物製药的发展

过去二十年，合成生物学领域取得了长足发展，重大技术创新提供了新的机会和巨大的增长潜力。合成生物学技术的进步彻底改变了药物发现和疗法开发，加速了新药物靶点的识别、高通量化合物筛选并促进了药物发现。对治疗学的贡献导致了更可持续和稳定的治疗方法的设计和开发。新的、有前景的合成生物学工具，例如基因电路和 CRISPR 系统，能够开发下一代细胞疗法、抗体和具有治疗活性的人造生物体。下一代疗法的兴起可能会在未来几年变得突出，特别是在利用合成生物学开发 CAR-T 细胞免疫疗法方面，因为它具有精确和个性化的能力。

Frost & Sullivan 指出，随着世界走向精准医疗，新兴的合成生物学生态系统正在跨地区发展。学术界、初创新兴企业正在大力研究和开发针对癌症、传染病和罕见疾病的合成生物学驱动疗法。

合成生物学平台也广泛用于治疗药物的生物製造，使公司能够根据商业需求经济高效地扩展治疗药物。技术发展将推动合成生物学工具在世界各地的采用，推动融资生态系统并带来高增长机会。

本报告提供的信息包括：

  • 增长促进因素和抑制因素（2023-2027）
  • 支持药物发现的合成生物学技术的发展
  • 合成生物学治疗剂开发中的关键问题及对策
  • 全球潜在市场进入者

目录

战略问题

  • 为什么成长如此困难？战略要务 8 (TM)：增长的障碍
  • The Strategic Imperative 8 (TM)
  • 合成生物学在药物发现和治疗行业中的战略问题：三大影响
  • 通过增长机会加速增长管道引擎 (TM)
  • 调查方法

增长机会分析

  • 合成生物学正在成为研究和开发中一个有前途的工具
  • 增长促进因素
  • 生长抑制因素
  • 分析范围
  • 分割
  • 技术成熟度
  • 新兴企业（2020-2022）
  • 趋势
  • 主要发现

药物发现中的技术创新和研发场景

  • 通过遗传电路和 CRISPR 系统识别新靶标
  • 加速先进疗法设计和开发的合成生物学平台
  • 合成生物学在药物发现管道中的作用
  • 通过合成生物学驱动的方法进行靶点识别和药物分子筛选
  • 先进的 CRISPR 系统改善药物靶点筛选
  • 复杂的基因迴路作为药物发现的实时监测工具
  • 利用先进的合成电路平台实现高通量药物筛选和选择
  • 利用器官芯片和类器官系统加速合成生物学驱动的药物发现
  • 改进合成生物学工具的设计以应对药物发现挑战
  • 扩大合成生物学驱动的药物发现公司网络

治疗药物创新及研发场景

  • 使用合成生物学工具开发下一代疗法
  • 使用合成生物学工具实现受控治疗反应
  • 合成生物学平台的引入将改变全球疾病的治疗
  • 利用合成生物学工具开发先进的疗法和疫苗
  • 行业参与者使用合成生物学工具开发先进的疗法和疫苗
  • 利用合成生物学工具开发智能细胞疗法
  • 逻辑门：通过精确的开关机制提高工程细胞的活性
  • 研发：专注于开发合适的合成生物学电路/系统
  • 研究人员利用基因电路开发可编程医学
  • 用作治疗剂的多功能底盘生物体：改善可扩展性和药物输送
  • 综合工程微生物疗法的开发
  • 作为活疗法的工程微生物

促进药物发现和治疗药物生产规模扩大的合成生物学工具

  • 通过生物传感器识别药物靶点并敏感地释放治疗剂
  • 利用基因电路进行治疗药物的无细胞生物製造
  • 无细胞生物製造系统的用途和需求不断扩大

资金和合作伙伴关係

  • 促进全球筹款工作，支持合成生物学平台的发展
  • 旨在提高合成生物学平台能力的併购数量不断增加
  • 扩大与合成生物学治疗开发商和製药公司的合作伙伴关係
  • 利用世界合成生物学平台加速药物发现和治疗

未来

  • 合成生物学治疗的差距分析
  • 基于基因迴路释放疗法的生物细胞疗法

充满增长机会的宇宙

  • 增长机会1：利用合成基因迴路提高CAR-T细胞疗法的长期疗效
  • 增长机会二：推动协同研究，打造融合合成生物学平台
  • 增长机会 3：简化在治疗中使用合成基因迴路的监管途径

附录

  • 利用先进的合成生物学 DBTL 循环加速药物发现

下一步

  • 下一步
  • 为什么选择 Frost & Sullivan？为什么选择现在？
  • 免责声明
简介目录
Product Code: DAA1

Disruptive Technology Advances in SynBio Foster a Thriving Stakeholder Ecosystem and Accelerate Biopharma Developments

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening and easing drug discovery. Its contribution to therapeutics has resulted in the design and development of more sustainable and stable therapies. Emerging and promising SynBio tools, such as gene circuits and CRISPR systems, enable the development of next-generation cell therapies, antibodies, and engineered organisms with therapeutic effects. The rise in next-generation therapeutics will be evident in the coming years, especially in developing CAR-T cell immunotherapy using Synbio, as it can provide accuracy and personalization.

Frost & Sullivan notes a rise in the SynBio start-up ecosystem across regions as the world moves toward precision medicine. Intense R&D efforts are ongoing in academia, start-ups, and big pharmaceutical companies toward developing SynBio-driven therapies for cancer, infectious diseases, and rare diseases.

Therapeutics biomanufacturing also widely uses SynBio platforms, allowing companies to scale therapeutics based on commercial requirements cost-efficiently. Technology developments will boost the global adoption of SynBio tools, encourage the funding ecosystems, and move toward high-growth opportunities.

Information provided in this report includes the following:

  • Growth drivers and restraints (2023-2027)
  • Developments in SynBio technologies supporting drug discovery
  • Critical challenges in developing SynBio therapeutics and the steps taken to address them
  • Global market participants with potential

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on SynBio in the Drug Discovery and Therapeutics Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™
  • Research Methodology

Growth Opportunity Analysis

  • SynBio Emerges as a Promising Tool in R&D
  • Growth Drivers
  • Growth Restraints
  • Scope of Analysis
  • Segmentation
  • Technology Maturity
  • Emerging Companies, 2020-2022
  • Trends
  • Key Findings

Technology Innovations and R&D Scenario in Drug Discovery

  • Gene Circuits and CRISPR Systems Identify Novel Targets
  • SynBio Platforms Accelerate the Design and Development of Advanced Therapeutics
  • Role of SynBio Approaches in the Drug Discovery Pipeline
  • Target Identification and Drug Molecule Screening Using SynBio-driven Approaches
  • Advanced CRISPR Systems for Improved Drug Target Screening
  • Complex Gene Circuits Act as a Tool for Real-time Monitoring of Drug Discovery
  • Advanced Synthetic Circuit Platforms Enable High-throughput Drug Screening and Selection
  • Organ-on-a-chip and Organoid Systems Speed SynBio-driven Drug Discovery
  • Improving the Design of SynBio Tools to Address Challenges in Drug Discovery
  • The Growing Network of SynBio-driven Drug Discovery Companies

Technology Innovations and R&D Scenario in Therapeutics

  • Developing Next-generation Therapeutics Using SynBio Tools
  • Controlled Therapeutic Responses Achieved Using SynBio Tools
  • SynBio Platform Adoption Can Transform Global Disease Treatment
  • Developing Advanced Therapeutics and Vaccines with SynBio Tools
  • Industry Players Developing Advanced Therapeutics and Vaccines Using SynBio Tools
  • SynBio Tools Enable the Development of Smart Cell Therapies
  • Logic Gates Improve the Engineered Cellular Activity with a Precise Switch On/Off Mechanism
  • R&D Efforts Focus on Developing Suitable SynBio Circuit/System
  • R&D Players Developing Programmable Medicine Using Gene Circuits
  • Multifunctional Chassis Organisms Used as Therapeutics Improve Scalability and Delivery
  • Developing Synthetically Engineered Microbiome Therapies
  • Engineered Microorganisms n Functioning as Live Therapeutics

SynBio Tools Facilitating Drug Discovery and Scaling Up Therapeutic Production

  • Biosensors Identify Drug Targets and Release Therapeutics with Sensitivity
  • Cell-free Biomanufacturing of Therapeutics Using Gene Circuits
  • Growing Applications and Demand for Cell-free Biomanufacturing Systems

Funding and Partnerships Landscape

  • Encouraging Global Funding Activities to Boost the Growth f SynBio Platforms
  • Growing Mergers & Acquisitions o Improve SynBio Platform Capabilities
  • Growing Partnerships Between SynBio Therapy Developers and Pharmaceutical Companies
  • Global SynBioPlatforms or Accelerated Drug Discovery and Therapeutics

The Road Ahead

  • Gap Analysis for SynBio-based Therapies
  • Living ell Therapeutics to Release Therapies Based on Gene Circuits

Growth Opportunity Universe

  • Growth Opportunity 1: Improve the Long-term Efficiency of CAR-T Cell Therapies Using Synthetic Gene Circuits
  • Growth Opportunity 2: Foster Collaborations to Build Convergent SynBio Platforms
  • Growth Opportunity 3: Streamline Regulatory Pathways for Using Synthetic Gene Circuits in Therapeutics

Appendix

  • Advanced SynBio DBTL Cycle Speeds Drug Discovery

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • Legal Disclaimer